Cardiac Dimensions has received CE mark approval for its carillon mitral contour system, a novel therapy for treating heart failure patients suffering from functional mitral regurgitation (FMR).
The mitral contour system consists of a proprietary, implantable device with a percutaneous catheter delivery system.
The approval is backed by Amadeus and Titan clinical trials of the Carillon system, which demonstrated reduction in FMR and improvement in functional capacity and quality of life.
Another study, called Titan II, was recently initiated to further the clinical experience.
Commercial launch of the device in Europe will begin in 2012, the company said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData